Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SelPine-TZ is a combination antibiotic injection marketed by Unifaith Biotech, primarily used for treating moderate to severe bacterial infections, including those caused by resistant organisms. It is a fixed-dose combination containing cefepime, a fourth-generation cephalosporin, and tazobactam, a beta-lactamase inhibitor. Cefepime exerts its bactericidal activity by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs). Tazobactam is added to expand the spectrum of activity against beta-lactamase-producing bacteria by irreversibly inhibiting various beta-lactamase enzymes that would otherwise degrade cefepime. The product is typically available in a 1.125g strength (1000mg cefepime and 125mg tazobactam) for parenteral administration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SelPine-TZ.